U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505069) titled 'Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors' on March 10.
Brief Summary: RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent. This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target.
Study Start Date: Jan. 29
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: RT01-89Zr
Intravenous injection of RT01-89Zr with a dosage of 1-2 mCi
Recruitment Status: RECRUITING
Sponsor: Nanolattix Biotechnology Co., Ltd.
Published by HT Digi...